Personal Injury Law

Respiratory Inhaler May Pose Greater Stroke Risk

By Joe Saunders

The FDA is looking into whether Boehringer Ingelheim' respiratory inhaler poses a greater risk of stroke. According to the FDA, the data submitted by the German drug manufacturer, shows that its Spiriva Handihaler poses a greater risk of stroke compared with a placebo. FDA said it has not yet analyzed the figures, which were compiled from 29 patient studies. The FDA has asked doctors to report any adverse patient results while it waits for more data from the company in June.

Full post as published by Tampa Bay Personal Injury Law on March 19, 2008 (boomark / email).